Antiangiogenic therapies in endometriosis
review
OA: bronze
CC0
⤵ 31 in-corpus citations
AI-generated summary
This review examines antiangiogenic drugs like TNP470, endostatin, anginex, and rapamycin as potential endometriosis treatments, with preliminary animal model results warranting further investigation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Oral contraceptives, androgenic agents, progestins and gonadotropin-releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted that the growth of newly formed blood vessels is essential for the establishment and growth of endometriotic lesions; therefore, inhibition of angiogenesis may offer a new option for treatment of this disorder. In this paper, we reviewed anti-vascular endothelial growth factor agents and other angiostatic drugs (i.e., TNP470, endostatin, anginex, rapamycin) that have been studied in laboratory and animal models of endometriosis. Although preliminary results are interesting, further investigations are required before clinical trials can be planned in humans.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (21)
- Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane via openalex
- Antiangiogenesis Therapy for Endometriosis via openalex
- Antiangiogenic Agents Are Effective Inhibitors of Endometriosis via openalex
- Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions via openalex
- Endostatin inhibits the growth of endometriotic lesions but does not affect fertility via openalex
- EPIDEMIOLOGY OF ENDOMETRIOSIS via openalex
- Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis via openalex
- Future Perspectives in the Medical Treatment of Endometriosis via openalex
- Inhibition of endometriosis development in rhesus monkeys by blocking VEGF receptor: A novel treatment for endometriosis via openalex
- In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy via openalex
- Morphometric study of the stromal vascularization in peritoneal endometriosis via openalex
- Pain, quality of life and complications following the radical resection of rectovaginal endometriosis via openalex
- Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity via openalex
- Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation via openalex
- Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model via openalex
- W2005002677 via openalex
- W2130219955 via openalex
- W2036016293 via openalex
- W2002473063 via openalex
- W2144153179 via openalex
- W2133631530 via openalex
Cited by (31)
- Effects of pentoxifylline and metformin combination therapy compared to metformin alone in infertile women with symptomatic endometrioma 2024
- Importance of Medicinal Compounds from Traditional Plants for the Treatment of Endometriosis 2023
- Resveratrol impairs cellular mechanisms associated with the pathogenesis of endometriosis 2022
- Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate 2021
- Discerning Endometriosis as a Multifaceted Entity: A Comprehensive Review 2020
- Novel Medicine for Endometriosis and Its Therapeutic Effect in a Mouse Model 2020
- Endometriosis Pathogenesis and Management 2019
- Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going? 2019
- A comprehensive review of hormonal and biological therapies for endometriosis: latest developments 2019
- Investigational drugs for the treatment of endometriosis, an update on recent developments 2018
- Eutopic stromal cells of endometriosis promote neuroangiogenesis via exosome pathway† 2018
- Adenoviral vector encoding soluble Flt-1 engineered human endometrial mesenchymal stem cells effectively regress endometriotic lesions in NOD/SCID mice 2016
- Molecular Biology of Endometriosis 2016
- Endometriosis – Pathogenesis, Diagnosis, and Therapeutic Options for Clinical and Ambulatory Care 2013
- Mitigation of endometriosis using regenerative cerium oxide nanoparticles 2012
- Slit2 Overexpression Results in Increased Microvessel Density and Lesion Size in Mice With Induced Endometriosis 2012
- <i>Endostatin</i> Gene Therapy for Endometriosis in Rats 2012
- Antiangiogenic Drugs in the Treatment of Endometriosis 2012
- Novel Therapies Targeting Endometriosis 2011
- Endometriose - Entstehung, Diagnostik, Behandlungsmöglichkeiten und Probleme in Klinik und Praxis 2011
- Pharmacological treatment of endometriosis: update from recent clinical trials 2011
- XRCC1 399<sup>*</sup>Arg-related genotype and allele, but not XRCC1 His107Arg, XRCC1 Trp194Arg, KCNQ2, AT1R, and hOGG1 polymorphisms, are associated with higher susceptibility of endometriosis 2011
- Current pharmacotherapy for endometriosis 2010
- Pharmacological Treatment of Endometriosis 2009
- Fenofibrate causes regression of endometriotic implants: a rat model 2009
- Hibridação Genômica Comparativa em Endometriose 2008
- Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises 2008
- XRCC4 codon 247*A and XRCC4 promoter −1394*T related genotypes but not XRCC4 intron 3 gene polymorphism are associated with higher susceptibility for endometriosis 2008
- Endometriosis 2008
- Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo 2008
- Angiogenesis and antiangiogenic therapy in endometriosis 2007
Source provenance
- europepmc
- last seen: 2026-08-19T06:08:28.815611+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:15:12.369988+00:00
License: CC0
· commercial use OK